Treatment of Ebola Virus Infection with Antibodies from Reconvalescent Donors

Kreil, Thomas R.

doi:10.3201/eid2103.141838

Cited by 23 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, recent clinical evidence suggests that Abs present in Ebola virus–infected convalescent immune sera contribute to improved clinical outcomes in infected patients (Kreil, 2015; Lyon et al, 2014) and recently vesicular stomatitis virus (VSV) vaccination has been shown to drive robust humoral immune responses (Regules et al, 2015) that provide protection from infection (Henao-Restrepo et al, 2015). However, the specific mechanism(s) by which Abs provide protection remains unclear.…”

Section: Discussion/conclusionmentioning

confidence: 99%

Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology

Chung

Kumar

Arnold

et al. 2015

Cell

315

349

View full text Add to dashboard Cite

While antibody titers and neutralization are considered the gold standard for the selection of successful vaccines, these parameters are often inadequate predictors of protective immunity. As antibodies mediate an array of extra-neutralizing Fc-functions, when neutralization fails to predict protection, investigating Fc-mediated activity may help identify immunological correlates and mechanism(s) of humoral protection. Here, we used an integrative approach termed Systems Serology to analyze relationships among humoral responses elicited in four HIV vaccine-trials. Each vaccine regimen induced a unique humoral “Fc-fingerprint”. Moreover, analysis of case:control data from the first moderately protective HIV vaccine trial, RV144, pointed to mechanistic insights into immune complex composition that may underlie protective immunity to HIV. Thus, multi-dimensional relational comparisons of vaccine humoral fingerprints offer a unique approach for the evaluation and design of novel vaccines against pathogens for which correlates of protection remain elusive.

show abstract

Section: Discussion/conclusionmentioning

confidence: 99%

Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology

Chung

Kumar

Arnold

et al. 2015

Cell

315

349

View full text Add to dashboard Cite

show abstract

“…Furthermore, the administration of these antibodies likely prevents virus infection/replication/dissemination within the patient, rather than virus clearance. An important prerequisite to prevent infection with bloodborne diseases is that safety of virus-inactivated convalescent plasma transfusions is guaranteed, which can be challenging in EVD endemic areas [27]. Clinical trials were initiated in Guinea, Sierra Leone, and Liberia; without severe adverse reactions reported to date.…”

Section: Convalescent Plasma (Polyclonal Antibody Therapy)mentioning

confidence: 99%

Monoclonal antibodies for the treatment of Ebola virus disease

Moekotte

Huson

Ende³

et al. 2016

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Introduction: To date, the management of patients with suspected or confirmed Ebolavirus disease (EVD) depends on quarantine, symptomatic management and supportive care, as there are no approved vaccines or treatments available for human use. However, accelerated by the recent large outbreak in West Africa, significant progress has been made towards vaccine development but also towards specific treatment with convalescent plasma and monoclonal antibodies. Areas covered: We describe recent developments in monoclonal antibody treatment for EVD, encompassing mAb114 and the MB-003, ZMAb, ZMapp ™ and MIL-77E cocktails.Expert opinion: Preventive measures, are, and will remain essential to curb EVD outbreaks; even more so with vaccine development progressing. However, research for treatment options must not be neglected. Small-scale animal and individual human case studies show that monoclonal antibodies (mAbs) can be effective for EVD treatment; thus justifying exploration in clinical trials. Potential limitations are that high doses may be needed to yield clinical efficacy; epitope mutations might reduce efficacy; and constant evolution of (outbreak-specific) mAb mixtures might be required. Interim advice based on the clinical experience to date is that treatment of patients with mAbs is sensible, provided those could be made available in the necessary amounts in time.ARTICLE HISTORY

show abstract

“…The largest outbreak of Ebola virus infection is discussed in Ref. [88]. Such advanced superiorities would be perfect for fast, point-of-care detection of Ebola virus [89].…”

Section: Ebolamentioning

confidence: 99%